Abstracts tagged "Decision analysis"

Abstract Number: 1355 • 2019 ACR/ARP Annual Meeting
A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures
Grant Cannon¹, Wei Chen ¹, JIncheng Shen ², Neil Accortt ³, David Collier ⁴ and Brian Sauer ¹, ¹Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ²Univeristy of Utah, Salt Lake City, UT, ³Amgen, Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Despite ACR recommendations to initiate a major therapeutic change (MTC) in rheumatoid arthritis (RA) patients with moderate/severe disease activity, our recent work has shown…
Abstract Number: 411 • 2017 ACR/ARHP Annual Meeting
Factors That Drive Treatment Recommendation during Rheumatoid Arthritis Patient´s Follow-up, Differ According to Physician Experience
César Sifuentes-Cantú¹, Irazu Contreras-Yañez², Lina Saldarriaga Rivera³, Ana Cecilia Lozada⁴, Marwin Gutierrez⁵ and Virginia Pascual-Ramos¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ³Instituto Nacional de Rehabilitación, Mexico, Mexico, ⁴Division of musculoskeletal and rheumatic diseases, Instituto Nacional de Rehabilitación, Mexico City, Mexico, ⁵Rheumatology, Instituto Nacional de Rehabilitación, Mexico City, Mexico
Background/Purpose: The management plan for rheumatoid arthritis (RA) might be a relatively simple task if only disease activity is considered but might become more complex…
Abstract Number: 1045 • 2017 ACR/ARHP Annual Meeting
The Potential Value of a Shared Decision-Making Intervention for Choices Regarding Triple Therapy in Rheumatoid Arthritis
Nick Bansback¹, Tima Mohammadi², Aslam Anis³, James R. O'Dell⁴ and Glen Hazlewood⁵, ¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ²Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ³University of British Columbia, School of Population and Public Health, Vancouver, BC, Canada, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Previous studies have shown that using Triple Therapy (a combination of 3 generic drugs) prior to a biologic, is the most cost-effective strategy for…
Abstract Number: 1052 • 2017 ACR/ARHP Annual Meeting
Systematic Review of Modelling Approaches and Quality for the Cost Effectiveness of sequential Targeted Therapy in Patients with Rheumatoid Arthritis That Show an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor
Aliza Matusevich¹, Maria Suarez-Almazor¹, Scott B. Cantor² and Maria A. Lopez-Olivo¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: Results from cost-effectiveness analysis (CEAs) comparing treatment options for patients with rheumatoid arthritis (RA) who have an inadequate response to an initial tumor necrosis…
Abstract Number: 1078 • 2017 ACR/ARHP Annual Meeting
Initial Combination Therapy Versus Step-up Therapy Is More Effective and Less Costly As a Treat to Target Strategy for RA: A Markov Model Based upon the Dutch Rheumatoid Arthritis Monitoring Registry Cohorts
Celine J. van de Laar¹, Laura M.M. Steunebrink², Martijn A.H. Oude Voshaar³ and Harald E. Vonkeman⁴, ¹Transparency in Healthcare B.V., Hengelo, Netherlands, ²Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, ⁴koningsplein, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands
Background/Purpose: Adjusting medication of patients with rheumatoid arthritis (RA) until predefined disease activity targets are met, i.e. Treat to Target (T2T), is the currently recommended…
Abstract Number: 1257 • 2017 ACR/ARHP Annual Meeting
A Scoping Review of Contextual Factors of Patient Decision Aids in Osteoarthritis
Alexa Meara¹, Karine Toupin-April², Bev Shea³, Liana Fraenkel⁴, Jennifer Barton⁵, Peter Brooks⁶, Maarten de Wit⁷ and Peter Tugwell⁸, ¹Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Yale University, New Haven, CT, ⁵Oregon Health and Science University, Portland, OR, ⁶The University of Queensland, Sidney, Australia, ⁷EULAR standing committee of PARE, Zurich, Switzerland, ⁸Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada
Background/Purpose: Patient decision aids (PDAs) have been developed to help patients make informed health care decisions that are consistent with their values and preferences. Patients…
Abstract Number: 1298 • 2017 ACR/ARHP Annual Meeting
Tough Choices: Understanding the Medication Decision-Making Process for Women with Inflammatory Arthritis during Pregnancy and Lactation
Tayseer Haroun¹, Amanda M. Eudy^2,3,4,5, Malithi Jayasundara², W. Benjamin Nowell^6,7, Jeffrey R. Curtis⁸, Charlotte Whitney White⁹, Rachelle Crow-Hercher⁹, Seth D. Ginsberg¹⁰ and Megan E. B. Clowse^4,11, ¹Department of Medicine/Division of Rheumatology, Duke University Medical Center, Durham, NC, ²Rheumatology, Duke University Medical Center, Durham, NC, ³Duke University, Durham, NC, ⁴Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, ⁵Duke University Medical Center, Chapel Hill, NC, ⁶CreakyJoints/Global Health Living Foundation, Upper Nyack, NY, ⁷Global Healthy Living Foundation, Upper Nyack, NY, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Arthritis Power, Upper Nyack, NY, ¹⁰Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, ¹¹Duke University Medical Center, Durham, NC
Background/Purpose: With new data demonstrating medication compatibility in pregnancy and lactation, it is important to understand how this information can best reach patients. We sought…
Abstract Number: 2778 • 2017 ACR/ARHP Annual Meeting
Preventing Rheumatoid Arthritis: North American Perspectives of Patients and First-Degree Relatives on the Risk of Developing the Disease and of Potential Preventative Interventions
Mark Harrison¹, Luke Spooner², Marie Hudson³, Katherine Milbers⁴, Cheryl L. Koehn⁵, Axel Finckh⁶ and Nick Bansback⁷, ¹Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Division of Rheumatology, Jewish General Hospital, Lady David Institute for Medical Research, Montreal, QC, Canada, ⁴Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada, ⁵Arthritis Consumer Expert, Vancouver, BC, Canada, ⁶University Hospital of Geneva, Geneva, Switzerland, ⁷School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Increasingly, evidence suggests that treatment of people at risk of rheumatoid arthritis (RA) with anti-rheumatic drugs could prevent the onset of disease. Ongoing randomized…
Abstract Number: 51 • 2017 Pediatric Rheumatology Symposium
The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA
Joost Swart¹, Nico Wulffraat², Sytze de Roock³ and Pieter van Dijkhuizen⁴, ¹Pediatric Rheumatology/ Immunology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²Wilhelmina Children’s Hospital, Utrecht, Netherlands, ³Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: We wondered if with our current physician based strategy we really do reach improvement within 3 months and inactive disease within 12 months in…
Abstract Number: 2453 • 2015 ACR/ARHP Annual Meeting
Evidence-Based Decision Support for Pediatric Rheumatology Reduces Diagnostic Errors, with the Potential to Reduce Capacity Shortage
Balu Athreya¹, Mary Beth Son², Jonathan S. Hausmann³, Elizabeth Ang⁴, David Zurakowski⁵, Michael Segal⁶ and Robert Sundel⁷, ¹duPont Hospital for Children/Thomas Jefferson University, Wilmington, DE, ²Division of Immunology, Children's Hospital Boston, Boston, MA, ³Rheumatology, Children's Hospital Boston, Boston, MA, ⁴Paediatrics, University Children's Medical Institute, NUH, Singapore, Singapore, ⁵Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, ⁶SimulConsult, Chestnut Hill, MA, ⁷Immunology, Childrens Hospital, Boston, MA
Background/Purpose: This projects seeks to respond to the critical shortage of pediatric rheumatologists encapsulating the diagnostic information of the field in an advanced diagnostic decision…
Abstract Number: 779 • 2015 ACR/ARHP Annual Meeting
Mapping Perceptions of Medication Decision Making Facilitators: The Importance of Patient Context
Haiyan Qu¹, Jinoos Yazdany², W. Winn Chatham³, Ricahrd Shewchuk⁴ and Jasvinder A. Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of California, San Francisco, San Francisco, CA, ³Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴University fo Alabama at Birmingham, Birmingham, AL
Background/Purpose: Our objective was to derive a cognitive map of how stakeholders perceive patient-identified facilitators to establish a theoretical framework for the purpose of developing…
Abstract Number: 2104 • 2015 ACR/ARHP Annual Meeting
Influence on Treatment Decision Making of Providing Numerical Ranges of Side-Effect Risks
Nick Bansback^1,2, Mark Harrison³, William G Dixon⁴ and Paul Han⁵, ¹Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ²School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ³Centre for Health Evaluation and Outcomes Sciences, St Paul's Hospital, Vancouver, BC, Canada, ⁴Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵Center for Outcomes Research and Evaluation, Maine Medical Center, Portland, ME
Background/Purpose: Doctors and patients make treatment decisions after weighing benefits and harms. For harms, while people prefer treatments with smaller risks, how they react to…
Abstract Number: 2269 • 2015 ACR/ARHP Annual Meeting
Rheumatologists Consider Patient Preferences and Costs When Choosing Treatments for Rheumatoid Arthritis (RA) Patients. a Cross-European Discrete Choice Experiment
Monika Hifinger¹, Mickaël Hiligsmann², Sofia Ramiro³, Verity Watson⁴, Johan L. Severens⁵, Bruno Fautrel⁶, Loreto Carmona⁷, Till Uhlig⁸, Ronald van Vollenhoven⁹, Peggy Jacques¹⁰, Jacqueline Detert¹¹, Carlo Alberto Scirè¹², Florian Berghea¹³, Márta Péntek¹⁴, Jose canas Silva¹⁵, Andrew Keat¹⁶ and Annelies Boonen¹⁷, ¹Rheumatology, University of Maastricht, Maastricht, Netherlands, ²Department of Health Services Research, University of Maastricht, Maastricht, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Health Economics Research Unit, University of Aberdeen, Aberdeen, United Kingdom, ⁵Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands, ⁶Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁷Instituto de Salud Musculoesqueletica, Madrid, Spain, ⁸Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁹Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, ¹⁰University Hospital Ghent, Ghent, Belgium, ¹¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹²Italian Society for Rheumatology, Milan, Italy, ¹³Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, ¹⁴Corvinus University of Budapest, Budapest, Hungary, ¹⁵Rheumatology Department, Hospital Garcia de Orta, E.P.E., Almada, Portugal, ¹⁶Northwick Park Hospital, Harrow, United Kingdom, ¹⁷Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Economic considerations and patient preferences are increasingly important when choosing treatments. It is not known to what extent rheumatologists across Europe account for these…
Abstract Number: 2312 • 2015 ACR/ARHP Annual Meeting
Patient Preferences for Total Knee Replacement Surgery: Two Year Follow-up
Ernest Vina¹, Di Ran², Erin Ashbeck², Said Ibrahim³, Michael J. Hannon⁴, Jin Zhou⁵ and C. Kent Kwoh¹, ¹Rheumatology, University of Arizona, Tucson, AZ, ²Arthritis Center, University of Arizona, Tucson, AZ, ³Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵Epidemiology & Biostatistics, University of Arizona, Tucson, AZ
Background/Purpose: Patients’ preferences for total knee replacement (TKR) may determine actual receipt of TKR and may also change over time. Yet, no study has longitudinally…
Abstract Number: 2329 • 2015 ACR/ARHP Annual Meeting
Describe Treatments As ‘new’ or ‘old’ at Your Peril: Influences on Patient Decision Making
Mark Harrison^1,2, Carlo Marra³ and Nick Bansback^4,5, ¹Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ²Centre for Health Evaluation and Outcomes Sciences, St Paul's Hospital, Vancouver, BC, Canada, ³School of Pharmacy, Memorial University, St John's, NF, Canada, ⁴St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁵School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Using an example of a new drug for rheumatoid arthritis which offers comparable effectiveness and side-effect point estimates to older drugs, we explore preferences…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].